{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-140755","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.792898+00:00","generated_at":"2026-06-15T05:44:15.037726+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INOVIO Q1 2023 net loss $40.6M; VGX-3100 misses in biomarker population","bullets":["Net loss $40.6M ($0.16/sh) vs $79.1M ($0.36) in Q1 2022; revenue $115K vs $199K.","Cash and equivalents $223.8M as of March 31; runway projected into Q1 2025.","Phase 3 VGX-3100 for cervical HSIL missed primary endpoint in biomarker population but achieved statistical significance in all-participants.","INO-3107 for RRP: 10 of 11 (91%) patients saw reduction in surgical interventions; well-tolerated.","Appointed Dr. Cheryl Elder as SVP Regulatory Affairs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-140755","json":"https://secwatch.observer/filing/0001193125-23-140755.json","markdown":"https://secwatch.observer/filing/0001193125-23-140755.md","text":"https://secwatch.observer/filing/0001193125-23-140755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000119312523140755/0001193125-23-140755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000119312523140755/d425606d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:44:15.037726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d2f0a79ab833fae431ddee48387cf41279b4324","claim":"INOVIO PHARMACEUTICALS, INC. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 10, 2023, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1055726/000119312523140755/0001193125-23-140755-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}